Stock Taper
SCREENER COMPARE ANY 2 STOCKS
APLM
APOLLOMICS, INC.
NASDAQ
$26.60
▲ UP 1.14% (0.30)

KEY STATISTICS

Market Cap$58.41 M
52w High$42.12
52w Low$3.94
Dividend Yield—
Frequency—
P/E-3.51
Volume6.33K
Shares Out.2.20M

COMPANY

LEADERSHIP

Hung-Wen Chen
CHIEF EXECUTIVE
Hung-Wen Chen

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 26, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
14

UPCOMING EARNINGS

DateSep 24, 2026
DayThursday
Rev. Est.—
SEP
24
THU

SPLIT RECORD

DATETYPERATIO
2024-11-25Reverse1:100

PRICE

$26.60 ▲ UP 1.14% (+$0.30)
OVERLAYS
$26.00$26.50$27.00$27.509:40 AM10:43 AM11:46 AM12:50 PM1:53 PM2:56 PM3:59 PM26.60

About Apollomics, Inc.

https://www.apollomicsinc.com ↗

Apollomics, Inc. is a biotech firm developing oncology therapies like c-Met and tyrosine kinase inhibitors for various cancers, with operations in the U.S., China, and Australia.

INDUSTRY

Biotechnology

A PRODUCT APOLLOMICS, INC. IS KNOWN FOR

Vebreltinib (APL-101)
Vebreltinib (APL-101)

Vebreltinib is a potent, selective c-Met inhibitor developed by Apollomics for treating NSCLC and other advanced cancers with c-Met alterations, with conditional approval in China for certain cancer types.

COMPETITORS

COMPETITOR
AZN COMPARE
HCM COMPARE
NVS COMPARE
PFE COMPARE

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Huang Ya-Chi
Purchase · 500 shares
2026-08-17
★
DIRECTOR
Huang Ya-Chi
Sale · 500 shares
2026-08-17
★
DIRECTOR, OFFICER: CHIEF OPERATING OFFICER
Chen Yi-Kuei
Purchase · 20.0K shares
2026-08-14
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Chen Hung-Wen
Purchase · 166.7K shares
2026-08-14

SECTORS PEERS

PEERPRICE
ANL$13.82COMPARE
BLRX$2.60COMPARE
LNAI$2.37COMPARE
ICU$3.09COMPARE
GOVX$0.72COMPARE
MBRX$0.65COMPARE